Context Therapeutics Inc.
Support and Resistance Levels
Past performance
News About CNTX
All events for CNTX
All deals for CNTX
Financial Ratios
Financial Statements
CNTX vs Sector & Peers
About Context Therapeutics Inc.
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania. Website contexttherapeutics.com
Headquarters Philadelphia, PA, US